- **Title:** White blood cells and severe COVID-19: a Mendelian randomization study
- $\frac{2}{3}$
- 3 Yitang Sun¹, Jingqi Zhou^{1,2}, Kaixiong Ye^{1,3,*}
- $\frac{4}{5}$
	- Department of Genetics, Franklin College of Arts and Sciences, University of Georgia,
- Athens, GA, USA
- ² School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai,
- P.R. China
- 9 ³ Institute of Bioinformatics, University of Georgia, Athens, GA, USA
-

* **Address for Correspondence:**

-
- Dr. Kaixiong Ye
- Department of Genetics
- University of Georgia
- C220 Davison Life Sciences
- 120 East Green Street, Athens, GA 30602
- Office: 706-542-5898
- Fax: 706-542-3910
-

Email: Kaixiong.Ye@uga.edu

Abstract

Background: The pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly emerged to seriously threaten public health. We aimed to investigate whether white blood cell traits have potential causal effects on severe COVID-19 using Mendelian randomization (MR).

Methods: To evaluate the causal associations between various white blood cell traits and severe COVID-19, we conducted a two-sample MR analysis with summary statistics from recent large genome-wide association studies.

Results: Our MR results indicated potential causal associations of white blood cell count, myeloid white blood cell count, and granulocyte count with severe COVID-19, with odds ratios (OR) of 0.84 (95% CI: 0.72-0.98), 0.81 (95% CI: 0.70-0.94), and 0.84 (95% CI: 0.71-0.99), respectively. Increasing eosinophil percentage of white blood cells was associated with a higher risk of severe COVID-19 (OR: 1.22, 95% CI: 1.03- 1.45).

Conclusions: Our results suggest the potential causal effects of lower white blood cell count, lower myeloid white blood cell count, lower granulocyte count, and higher eosinophil percentage of white blood cells on an increased risk of severe COVID-19.

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.10.14.20212993;](https://doi.org/10.1101/2020.10.14.20212993) this version posted October 18, 2020. The copyright holder for this preprint

Key Words: COVID-19; white blood cells; eosinophil; Mendelian randomization

Background

Coronavirus disease 2019 (COVID-19) is caused by infection of a novel virus called 48 Severe Acute Respiratory Syndrome Coronavirus 2 (SARSZCoVZ2) [1]. SARSZCoVZ2 has rapidly spread, causing damage or even death [2-4]. Besides age and gender, some pre-existing conditions are also well-known to be associated with an increased risk of severe COVID-19, such as cardiovascular disease, diabetes, chronic respiratory disease, hypertension, and cancers [4-7]. Recently, genetic studies, including two genome-wide association studies (GWAS), have identified multiple genetic loci to be associated with the susceptibility and severity of COVID-19 [8-10]. However, causal risk factors for severe COVID-19 remain unclear. Identifying host factors predisposing individuals to severe COVID-19 is urgently needed to improve primary prevention and to develop treatment strategies.

Elevated white blood cell and neutrophil counts, and depleted lymphocyte count have been repeatedly observed in COVID-19 patients with severe outcomes, and neutrophil-to-lymphocyte ratio have been proposed as a prognostic biomarker [1, 11-14]. However, findings from recent observational studies are inconsistent and the exact roles of white blood cells and its various subtypes in severe COVID-19 remain elusive [15-17]. Most existing studies measured blood cell counts in patients with confirmed infection of SARS-CoV-2 and as a result, the hematological indices could have been modified by immune responses [18]. It is unknown if blood cell counts before infection are

associated with the risk of developing severe COVID-19. Even if white blood cells are measured before infection, they are influenced by many exogenous and endogenous factors (e.g., age, gender, disease status, and medications), which will confound the observational associations [19, 20]. No previous research has been able to interrogate the causal role of white blood cells in severe COVID-19.

While traditional observational associations often suffer from confounding, reverse causality, and various biases, a complementary approach, Mendelian randomization (MR), utilizes genetic variants as instrumental variables to approximate the lifetime status of exposure and enable causal inference in observational data. The random allocation of the allele at conception and the natural directional effects of genetic variants empower MR estimates to be less plagued by confounding and reverse causality [21, 22]. In this study, we aimed to test the causal effects of 19 white blood cell traits on severe COVID-19 by performing a two-sample MR analysis.

Methods

Study design and data source

A two-sample MR study was conducted to examine the causal effects of 19 white blood cell traits on severe COVID-19. These blood cell traits were chosen based on a GWAS meta-analysis in 173,480 European ancestry individuals across three cohorts, and their summary statistics were available in the IEU OpenGWAS database [23, 24]. Genetic instruments for each white blood cell trait were chosen based on the following criteria: 1) $p < 8.31 \times 10^{-9}$ for association with the exposure; and 2) linkage disequilibrium (LD) 89 clumping based on $r^2 > 0.001$. The data source and details for 19 white blood cell traits are available in Supplementary Table 1. The instrument-outcome effects were retrieved from the largest GWAS meta-analysis of COVID-19 to date, by the COVID-19 Host Genetics Initiative (HGI, release 3, accessed on July 2, 2020) [10]. We used the summary statistics based on the comparison of hospitalized COVID-19 patients (N = $3,199$) with the general population (N = 897,488).

Statistical analysis

The causal effect of a white blood cell trait on severe COVID-19 was evaluated using the inverse variance-weighted (IVW) method with a multiplicative random-effects model [22, 25, 26]. Horizontal pleiotropy occurs when SNPs exert a direct effect on the severe COVD-19 through pathways other than the hypothesized exposure. To evaluate the possible presence of horizontal pleiotropy, we calculated Cochran's Q statistic for 102 heterogeneity and conducted the intercept test associated with the MR-Egger method. Additional sensitivity analyses were performed with MR-Egger [22, 26], weighted

median (WM) [27], and Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) test [28]. The MR-Egger estimates allowed directional or unbalanced horizontal pleiotropic effects. The weighted median method provides robust causal estimates even when up to 50 % SNPs are invalid genetic instruments [27]. The MR-PRESSO test was utilized to correct for the presence of specific horizontal pleiotropic outlier variants via detected outlier removal [28]. All MR analyses were conducted in R with the TwoSampleMR package [23].

Resources

- The COVID-19 Host Genetics Initiative: https://www.covid19hg.org/
- 114 The IEU OpenGWAS database: https://gwas.mrcieu.ac.uk/

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.10.14.20212993;](https://doi.org/10.1101/2020.10.14.20212993) this version posted October 18, 2020. The copyright holder for this preprint

Results

The counts of white blood cell, myeloid white blood cell, and granulocyte are negatively associated with severe COVID-19

By applying a two-sample MR approach, we first investigated the causal associations of the counts of white blood cell and its subpopulations with severe COVID-19. A relatively large number of independent SNPs, ranging from 79 for basophil count to 185 for monocyte count, were selected as genetic instruments for each blood cell count (Supplementary Tables 2-11). Based on the IVW MR estimates under a multiplicative random-effects model, we identified potentially causal, negative associations of white blood cell count (OR = 0.84, CI: 0.72-0.98, *p* = 0.031), basophil count (OR = 0.75, CI: 0.58-0.96, *p* = 0.023), myeloid white blood cell count (OR = 0.81, CI: 0.70-0.94, *p* = 0.0070), and granulocyte count (OR = 0.84, CI: 0.71-0.99, *p* = 0.040) with severe COVID-19 (Fig. 1, Table 1). A suggestive negative association was also found for sum neutrophil eosinophil counts (OR = 0.85, CI: 0.73-1.00, *p* = 0.051). No evidence of heterogeneity in causal estimates was found by the Cochran Q statistic, and no evidence of horizontal pleiotropy was reported by the MR-Egger intercept test, except 131 for basophil count ($p = 0.036$). Causal estimates from MR-Egger and WM MR revealed broadly concordant effect directions, although they are mostly not statistically significant, probably due to the reduced power of these two approaches [26] (Supplementary Fig. 1, Supplementary Table 21). MR-PRESSO analysis did not identify any outlier SNPs and yielded significant causal estimates for white blood cell count (*p* = 0.033), myeloid white 136 blood cell count $(p = 0.0078)$, and granulocyte count $(p = 0.041)$ (Supplementary Table 21). Taken together, we demonstrated that white blood cell count, myeloid white blood

cell count, and granulocyte count had consistent, negative effects on the risk of severe COVID-19.

The percentage of eosinophil in white blood cell is positively associated with

severe COVID-19

We further investigated the causal associations of the percentages of specific white blood cells with severe COVID-19. As genetic instruments, we used 158 SNPs for eosinophil percentage, 63 SNPs for basophil percentage, 135 SNPs for the neutrophil percentage, 191 SNPs for monocyte percentage, and 135 SNPs for lymphocyte percentage (Supplementary Tables 12-16).

Genetically predicted higher eosinophil percentage of white blood cells (OR = 1.22, CI: 150 1.03-1.45, $p = 0.023$) was associated with increased risk of severe COVID-19 using IVW with the random-effect model (Figure 1). The WM MR method and the MR-PRESSO analysis both revealed a consistent, positive effect (OR = 1.41, CI: 1.07-1.87, *p* = 0.015; and OR = 1.22, CI: 1.03-1.45, *p* = 0.024; respectively. Supplementary Table 21). No pleiotropy or outlier SNPs were identified in the MR-Egger test and MR-PRESSO analysis. Cochran Q statistics indicated no heterogeneity among the genetic instruments (Supplementary Table 21).

The percentage of eosinophil in granulocyte is positively associated with severe COVID-19

We further focused on the granulocyte and evaluated if it specific compositions are associated with severe COVID-19. As genetic instruments, there were 168 SNPs for granulocyte percentage of myeloid white blood cells, 150 SNPs for eosinophil percentage of granulocytes, 59 SNPs for basophil percentage of granulocytes, and 141 SNPs for the neutrophil percentage of granulocytes (Supplementary Tables 17-20). Our results found suggestive evidence for a risk-increasing effect of eosinophil percentage of granulocytes on severe COVID-19 (OR = 1.18, CI: 1.00-1.39, *p* = 0.053). The WM MR method and the MR-PRESSO analysis both revealed a consistent positive effect (OR = 1.35, CI: 1.03-1.75, *p* = 0.029; and OR = 1.18, CI: 1.00-1.39, *p* = 0.055; respectively). No evidence of heterogeneity and pleiotropy was found. No statistically significant causal associations were identified for other specific granulocyte percentages (Figure 1 and Supplementary Table 21).

Discussion

To our knowledge, this is the first MR study evaluating the causal roles of white blood cell traits in severe COVID-19 risk. Overall, our results suggest potential causal protective effects of increasing white blood cell count, myeloid white blood cell count, and granulocyte count on severe COVID-19. Our novel findings also include that genetically predicted higher eosinophil percentage in white blood cells or in granulocytes was associated with a higher risk of severe COVID-19.

Previous observational studies have frequently pointed out increased white blood cell count in the severe COVID-19 patients, when compared to healthy controls or mild COVID-19 patients [1, 11, 12, 29]. However, there are also reports that normal or decreased white blood cell count is more common in COVID-19 patients when compared to the reference range or healty controls [10, 15-17, 30-32]. Our MR analysis showed that lower white blood cell count, myeloid white blood cell count, and granulocyte count may play a causal role in increasing the risk of severe COVID-19. The mechanism by which they contribute to severe COVID-19 remains unclear. Immune system disorders have been suspected of playing roles in severe COVID-19 risk [33, 34]. The complete elucidation of the potential mechanism warrants further investigation.

Persistent eosinopenia after admission was associated with COVID-19 risk in previous retrospective and prospective observational studies [12, 15, 31, 32, 35-37]. There are also reports that eosinophil remains stable in severe COVID-19 patients [13, 29, 38, 39]. A multiparametric flow cytometry analysis found that high eosinophil count was

associated with an increased risk of severe COVID-19 [13]. Another observational study suggested that increasing eosinophil count might be an indicator of COVID-19 improvement [40]. Our MR analysis supported that high eosinophil percentage of white blood cells may be causal in increasing the risk of severe COVID-19 [40, 41], calling for future mechanistic studies.

Lymphopenia, as a response to viral infection, has been frequently associated with severe COVID-19 risk [1, 2, 13, 29, 41-51]. However, we did not detect a causal effect of lymphocyte count on severe COVID-19. This discrepancy may reflect reverse causality in retrospective and prospective observational studies, with depleted 205 Iymphocyte count as a result of immune response to $SARS@Cov@2$ infection [52]. Due to the limited number of SNPs associated with severe COVID-19, performing reverse MR analyses between severe COVID-19 and white blood cell traits is challenging. Using linkage disequilibrium (LD) assessment, only one SNP at locus 3p21.31 was retained in the previously published genome-wide significant SNPs [10]. We recently showed that SNPs at this locus are associated with multiple blood cell traits, suggesting they may have pleiotropic effects and are not suitable to be used as genetic instruments [53]. As more COVID-19-associated SNPs are identified in the future, reverse MR analysis will be valuable to understand the effect of COVID-19 on blood cell traits.

One assumption of MR is that the instrumental variable influences severe COVID-19 risk only through its effect on a specific white blood cell trait. The Cochran Q statistic did not reveal heterogeneity among our genetic instruments, and the MR-Egger intercept

- 218 test also indicated no presence of pleiotropic effects except those for basophil count.
- 219 Our MR study was performed with strong instrumental variables and adequate statistical
- 220 power, and we have conducted extensive sensitivity analyses. Still, we emphasize that
- 221 our results should be interpreted with caution and future studies are needed to elucidate
- 222 the mechanistic roles of white blood cell traits in severe COVID-19.

Conclusions

- Our results suggest that lower white blood cell count, lower myeloid white blood cell
- count, lower granulocyte count, and higher eosinophil percentage of white blood cells
- are causally associated with an increased risk of severe COVID-19.

List of abbreviations

- COVID-19: coronavirus disease 2019
- SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
- MR: Mendelian randomization
- GWAS: genome-wide association studies
- SNPs: single nucleotide polymorphisms
- LD: linkage disequilibrium
- HGI: Host Genetics Initiative
- IEU: Integrative Epidemiology Unit
- IVW: inverse variance-weighted
- WM: weighted median
- MR-PRESSO: Mendelian randomization pleiotropy residual sum and outlier

Declarations

Ethics approval and consent to participate

- Ethical approval from the North West Multi-Centre Research Ethics Committee and
- written informed consent from all participants were obtained.

- **Consent for publication**
- Not applicable.

- **Availability of data and materials**
- All data generated or analyzed during this study are included in this published article
- and this supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Funding

- KY is supported by the University of Georgia Research Foundation. Funding sources
- had no involvement in the conception, design, analysis, or presentation of this work.

Authors' contributions

- YS, JZ, and KY conceived the study. YS performed data analysis and prepared
- visualizations. YS, JZ, and KY interpreted the results. YS and KY wrote the first draft of

- 261 the manuscript. All authors critically read, revised, and approved the final version of the
- manuscript.
-

Acknowledgments

- We would like to express our gratitude to all other Ye lab members for stimulating
- discussions.
-

ReferencesUncategorized References

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X *et al*: **Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study**. *Lancet* 2020, **395**(10229):1054-1062. 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X *et al*: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China**. *Lancet* 2020, **395**(10223):497-506. 3. Wenham C, Smith J, Morgan R, Gender, Group C-W: **COVID-19: the gendered impacts of the outbreak**. *Lancet* 2020, **395**(10227):846-848. 4. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia P, D'Acquisto F *et al*: **COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options**. *Cardiovasc Res* 2020, **116**(10):1666-1687. 5. Teng Y, Xu J, Zhang Y, Liu Z, Zhang S: **Mendelian randomization in COVID-19: Applications for cardiovascular comorbidities and beyond**. *EBioMedicine* 2020, **57**:102847. 6. Wu Z, McGoogan JM: **Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention**. *JAMA* 2020. 7. Rao S, Lau A, So HC: **Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits**. *Diabetes Care* 2020, **43**(7):1416-1426. 8. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, van Deuren RC, Steehouwer M, van Reijmersdal SV, Jaeger M *et al*: **Presence of Genetic Variants Among Young Men With Severe COVID-19**. *JAMA* 2020. 9. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernandez J, Prati D, Baselli G, Asselta R *et al*: **Genomewide Association Study of Severe Covid-19 with Respiratory Failure**. *N Engl J Med* 2020. 10. Initiative C-HG: **The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic**. *Eur J Hum Genet* 2020, **28**(6):715-718. 11. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q *et al*: **Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China**. *JAMA Cardiol* 2020, **5**(7):802-810. 12. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W *et al*: **Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China**. *Clin Infect Dis* 2020, **71**(15):762-768. 13. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, Agyekum RS, Mathew D, Baxter AE, Vella LA *et al*: **Comprehensive mapping of immune perturbations associated with severe COVID-19**. *Sci Immunol* 2020, **5**(49). 14. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R *et al*: **Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019**

coronavirus disease in the early stage. *J Transl Med* 2020, **18**(1):206.

15. Xie G, Ding F, Han L, Yin D, Lu H, Zhang M: **The role of peripheral blood eosinophil counts in COVID-19 patients**. *Allergy* 2020. 16. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH *et al*: **Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province**. *Chin Med J (Engl)* 2020, **133**(9):1025-1031. 17. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA: **Hematological findings and complications of COVID-19**. *Am J Hematol* 2020, **95**(7):834-847. 18. Siedlinski M, Jozefczuk E, Xu X, Teumer A, Evangelou E, Schnabel RB, Welsh P, Maffia P, Erdmann J, Tomaszewski M *et al*: **White Blood Cells and Blood Pressure: A Mendelian Randomization Study**. *Circulation* 2020, **141**(16):1307-1317. 19. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S *et al*: **Viral and host factors related to the clinical outcome of COVID-19**. *Nature* 2020, **583**(7816):437-440. 20. Zhao K, Li R, Wu X, Zhao Y, Wang T, Zheng Z, Zeng S, Ding X, Nie H: **Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis**. *Eur J Clin Microbiol Infect Dis* 2020. 21. Davies NM, Holmes MV, Davey Smith G: **Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians**. *BMJ* 2018, **362**:k601. 22. Burgess S, Davey Smith G, Davies N, Dudbridge F, Gill D, Glymour M, Hartwig F, Holmes M, Minelli C, Relton C *et al*: **Guidelines for performing Mendelian randomization investigations [version 2; peer review: 1 approved, 1 approved with reservations]**. *Wellcome Open Research* 2020, **4**(186). 23. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R *et al*: **The MR-Base platform supports systematic causal inference across the human phenome**. *Elife* 2018, **7**. 24. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H, Riveros-Mckay F, Kostadima MA *et al*: **The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease**. *Cell* 2016, **167**(5):1415- 1429 e1419. 25. Burgess S, Butterworth A, Thompson SG: **Mendelian randomization analysis with multiple genetic variants using summarized data**. *Genet Epidemiol* 2013, **37**(7):658-665. 26. Bowden J, Davey Smith G, Burgess S: **Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression**. *Int J Epidemiol* 2015, **44**(2):512-525. 27. Bowden J, Davey Smith G, Haycock PC, Burgess S: **Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator**. *Genet Epidemiol* 2016, **40**(4):304-314. 28. Verbanck M, Chen CY, Neale B, Do R: **Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases**. *Nat Genet* 2018, **50**(5):693-698. 29. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD: **Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China**. *Allergy* 2020, **75**(7):1730-1741.

30. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, qi Y, Sun R, Tian Z, Xu X, Wei H: **Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients**. *Natl Sci Rev* 2020:nwaa041. 31. Sun DW, Zhang D, Tian RH, Li Y, Wang YS, Cao J, Tang Y, Zhang N, Zan T, Gao L *et al*: **The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel?** *Clin Chim Acta* 2020, **508**:122-129. 32. Li Q, Ding X, Xia G, Chen HG, Chen F, Geng Z, Xu L, Lei S, Pan A, Wang L *et al*: **Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study**. *EClinicalMedicine* 2020, **23**:100375. 33. Jesenak M, Brndiarova M, Urbancikova I, Rennerova Z, Vojtkova J, Bobcakova A, Ostro R, Banovcin P: **Immune Parameters and COVID-19 Infection - Associations With Clinical Severity and Disease Prognosis**. *Front Cell Infect Microbiol* 2020, **10**:364. 34. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Bruggen MC, O'Mahony L, Gao Y, Nadeau K, Akdis CA: **Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19**. *Allergy* 2020, **75**(7):1564-1581. 35. Wang D, Li R, Wang J, Jiang Q, Gao C, Yang J, Ge L, Hu Q: **Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study**. *BMC Infect Dis* 2020, **20**(1):519. 36. Gong J, Dong H, Xia SQ, Huang YZ, Wang D, Zhao Y, Liu W, Tu S, Zhang M, Wang Q *et al*: **Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia**. 2020:2020.2002.2025.20025643. 37. Tanni F, Akker E, Zaman MM, Figueroa N, Tharian B, Hupart KH: **Eosinopenia and COVID-19**. *J Am Osteopath Assoc* 2020. 38. Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, Shi CW, Lian X, Chu JG, Chen L *et al*: **Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series**. *QJM* 2020, **113**(7):474-481. 39. Lippi G, Henry BM: **Eosinophil count in severe coronavirus disease 2019**. *QJM* 2020, **113**(7):511-512. 40. Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, Yu W, Zhang J: **Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression**. *Int J Infect Dis* 2020, **95**:183-191. 41. Sun S, Cai X, Wang H, He G, Lin Y, Lu B, Chen C, Pan Y, Hu X: **Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China**. *Clin Chim Acta* 2020, **507**:174-180. 42. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD *et al*: **Immunology of COVID-19: Current State of the Science**. *Immunity* 2020, **52**(6):910-941.

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.10.14.20212993;](https://doi.org/10.1101/2020.10.14.20212993) this version posted October 18, 2020. The copyright holder for this preprint

43. Rothan HA, Byrareddy SN: **The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak**. *J Autoimmun* 2020, **109**:102433. 44. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y *et al*: **Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China**. *JAMA* 2020, **323**(11):1061-1069. 45. Ding Q, Lu P, Fan Y, Xia Y, Liu M: **The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China**. *J Med Virol* 2020. 46. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC *et al*: **Clinical Characteristics of Coronavirus Disease 2019 in China**. *N Engl J Med* 2020, **382**(18):1708-1720. 47. Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D: **Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia**. *AJR Am J Roentgenol* 2020, **215**(2):338-343. 48. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J *et al*: **Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China**. *J Infect* 2020, **80**(4):388-393. 49. Zhang MQ, Wang XH, Chen YL, Zhao KL, Cai YQ, An CL, Lin MG, Mu XD: **[Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing]**. *Zhonghua Jie He He Hu Xi Za Zhi* 2020, **43**(0):E013. 50. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, He MA, Cheng LX, Huang K, Zeng QT: **[Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]**. *Zhonghua Xin Xue Guan Bing Za Zhi* 2020, **48**(6):450-455. 51. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y *et al*: **Clinical features and treatment of COVID-19 patients in northeast Chongqing**. *J Med Virol* 2020, **92**(7):797-806. 52. Sattar N, Preiss D: **Reverse Causality in Cardiovascular Epidemiological Research: More Common Than Imagined?** *Circulation* 2017, **135**(24):2369-2372. 53. Zhou J, Sun Y, Huang W, Ye K: **Altered blood cell traits underlie a major genetic locus of severe COVID-19**. 2020:2020.2009.2009.20191700.

Tables

Table 1. Causal associations between white blood cell traits and severe COVID-19 based on random-effects IVW MR estimation.

Figure legends

Figure 1. Odds ratios for associations between genetically predicted risk factors and severe COVID-19. Analyses were done with the inverse variance-weighted (IVW) method with a multiplicative random-effects model. Effect estimates express the change in odds ratio (OR) per standard deviation (SD) increment in white blood cell traits, error bars indicate 95% confidence intervals. WBC#: White blood cell count; EO#: Eosinophil count; BASO#: Basophil count; NEUT#: Neutrophil count; MONO#: Monocyte count; LYMPH#: Lymphocyte count; MYELOID#: Myeloid white blood cell count; GRAN#: Granulocyte count; (NEUT+EO)#: Sum neutrophil eosinophil counts; (BASO+NEUT)#: Sum basophil neutrophil counts; EO%: Eosinophil percentage of white blood cells; BASO%: Basophil percentage of white blood cells; NEUT%: Neutrophil percentage of white blood cells; MONO%: Monocyte percentage of white blood cells; LYMPH%: Lymphocyte percentage of white blood cells; GRAN%MYELOID: Granulocyte percentage of myeloid white blood cells; EO%GRAN: Eosinophil percentage of granulocytes; BASO%GRAN: Basophil percentage of granulocytes; NEUT%GRAN: Neutrophil percentage of granulocytes.

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.10.14.20212993;](https://doi.org/10.1101/2020.10.14.20212993) this version posted October 18, 2020. The copyright holder for this preprint

Supplemental Data

- Supplementary Table 1. Summary of GWAS information for white blood cell phenotypes
- Supplementary Table 2. 167 SNPs used IVs in MR analyses testing effect of white
- blood cell count on severe COVID-19 risk.
- Supplementary Table 3. 169 SNPs used IVs in MR analyses testing effect of eosinophil
- count on severe COVID-19 risk.
- Supplementary Table 4. 79 SNPs used IVs in MR analyses testing effect of basophil
- count on severe COVID-19 risk.
- Supplementary Table 5. 140 SNPs used IVs in MR analyses testing effect of neutrophil
- count on severe COVID-19 risk.
- Supplementary Table 6. 185 SNPs used IVs in MR analyses testing effect of monocyte
- count on severe COVID-19 risk.
- Supplementary Table 7. 160 SNPs used IVs in MR analyses testing effect of lymphocyte count on severe COVID-19 risk.
- Supplementary Table 8. 146 SNPs used IVs in MR analyses testing effect of myeloid
- white blood cell count on severe COVID-19 risk.
- Supplementary Table 9. 144 SNPs used IVs in MR analyses testing effect of granulocyte count on severe COVID-19 risk.
- Supplementary Table 10. 139 SNPs used IVs in MR analyses testing effect of sum neutrophil eosinophil counts on severe COVID-19 risk.
- Supplementary Table 11. 142 SNPs used IVs in MR analyses testing effect of sum
- basophil neutrophil counts on severe COVID-19 risk.

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.10.14.20212993;](https://doi.org/10.1101/2020.10.14.20212993) this version posted October 18, 2020. The copyright holder for this preprint

- Supplementary Table 12. 158 SNPs used IVs in MR analyses testing effect of eosinophil percentage of white blood cells on severe COVID-19 risk.
- Supplementary Table 13. 63 SNPs used IVs in MR analyses testing effect of basophil
- percentage of white blood cells on severe COVID-19 risk.
- Supplementary Table 14. 135 SNPs used IVs in MR analyses testing effect of neutrophil
- percentage of white blood cells on severe COVID-19 risk.
- Supplementary Table 15. 191 SNPs used IVs in MR analyses testing effect of monocyte
- percentage of white blood cells on severe COVID-19 risk.
- Supplementary Table 16. 135 SNPs used IVs in MR analyses testing effect of lymphocyte percentage of white blood cells on severe COVID-19 risk.
- Supplementary Table 17. 168 SNPs used IVs in MR analyses testing effect of granulocyte percentage of myeloid white blood cells on severe COVID-19 risk.
- Supplementary Table 18. 150 SNPs used IVs in MR analyses testing effect of eosinophil percentage of granulocytes on severe COVID-19 risk.
- Supplementary Table 19. 59 SNPs used IVs in MR analyses testing effect of basophil percentage of granulocytes on severe COVID-19 risk.
- Supplementary Table 20. 141 SNPs used IVs in MR analyses testing effect of neutrophil
- percentage of granulocytes on severe COVID-19 risk.
- Supplementary Table 21. MR estimates from each method of assessing the causal effects of white blood cells on severe COVID-19 risk.
- Supplementary Figure 1. Scatter plots of the genetic associations of white blood cell count (A), or myeloid white blood cell count (B), or granulocyte count (C), or basophil
- count (D) or eosinophil percentage in white blood cells (E) associated SNPs against the

genetic associations of severe COVID-19. The slopes of each line represent the causal association using different MR methods. The light blue line represents the random-effects inverse variance-weighted estimate, the dark blue line represents the MR-Egger estimate, and the green line represents the weighted median estimate.

Tables

Table 1. Causal associations between white blood cell traits and severe COVID-19 based on random-effects IVW MR estimation.

WBC#: White blood cell count; EO#: Eosinophil count; BASO#: Basophil count; NEUT#: Neutrophil count; MONO#: Monocyte count; LYMPH#: Lymphocyte count; MYELOID#: Myeloid white blood cell count; GRAN#: Granulocyte count; (NEUT+EO)#: Sum neutrophil eosinophil counts; (BASO+NEUT)#: Sum basophil neutrophil counts; EO%: Eosinophil percentage of white blood cells; BASO%: Basophil percentage of white blood cells; NEUT%: Neutrophil percentage of white blood cells; MONO%: Monocyte percentage of white blood cells; LYMPH%: Lymphocyte percentage of white blood cells; GRAN%MYELOID: Granulocyte percentage of myeloid white blood cells; EO%GRAN: Eosinophil percentage of granulocytes; BASO%GRAN: Basophil percentage of granulocytes; NEUT%GRAN: Neutrophil percentage of granulocytes.

